Is KL-6 a serum indicator of early pulmonary fibrosis in childhood cancer patients?
Briassoulis
George
G
Pediatric Intensive Care Unit, Aghia Sophia Children's Hospital, Athens, Greece. briassg@otenet.gr
Stefanaki
Kalliopi
K
Peristeri
Ioulia
I
Endoh
Yasuhiro
Y
Hatzis
Tassos
T
D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000941:Antigens; D000951:Antigens, Neoplasm; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002675:Child, Preschool; D006023:Glycoproteins; D006801:Humans; D008297:Male; D018396:Mucin-1; D009077:Mucins; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000150:complications; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000209:etiology*; D017180:Tachycardia, Ventricular / Q000188:drug therapy* / Q000209:etiology
D000889:Anti-Arrhythmia Agents; D000941:Antigens; D000951:Antigens, Neoplasm; D015415:Biomarkers; D006023:Glycoproteins; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D000638:Amiodarone